Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q2 2019 · 10-Q
Revenue$79.05M$79.05M+11.3% vs Q2 2018 Net Income$47.79M$47.79MN/M vs Q2 2018 EPS Diluted$0.96$0.96N/M vs Q2 2018 Gross Profit$32,387,000+24.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$51,723,000+1,041.0% Free Cash Flowderived$42,000,000N/M Margins · derivedGross margin41.0%+4.3 pt vs Q2 2018
Operating margin1.2%+5.4 pt vs Q2 2018
Net margin60.5%+64.5 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 9, 2019 · 40 d after period end